Last $0.08 USD
Change Today 0.00 / 0.00%
Volume 1.5K
PARS On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

pharmos corp (PARS) Snapshot

Open
$0.08
Previous Close
$0.08
Day High
$0.08
Day Low
$0.08
52 Week High
01/30/14 - $0.19
52 Week Low
10/1/13 - $0.02
Market Cap
4.8M
Average Volume 10 Days
18.9K
EPS TTM
$-0.04
Shares Outstanding
60.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PHARMOS CORP (PARS)

Related News

No related news articles were found.

pharmos corp (PARS) Related Businessweek News

No Related Businessweek News Found

pharmos corp (PARS) Details

Pharmos Corporation, a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat a range of metabolic and nervous system disorders. The company focuses on the disorders of the brain-gut axis, pain/inflammation, and autoimmune, as well as gout disorders. Its lead compounds under clinically development include Levotofisopam, a non-sedating agent for the treatment of Gout; and Dextofisopam, a non-serotonergic agent which has completed Phase IIa and Phase IIb clinical trials for the treatment of irritable bowel syndrome. The company was founded in 1990 and is headquartered in Iselin, New Jersey.

2 Employees
Last Reported Date: 02/17/12
Founded in 1990

pharmos corp (PARS) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

pharmos corp (PARS) Key Developments

Pharmos Files Form 15

Pharmos Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock, par value $2.50 per share under the Securities Exchange Act of 1934, as amended.

Pharmos Corp. Announces Resignation of Friedman LLP as Independent Registered Accounting Firm

On January 2, 2013, Friedman LLP resigned as the independent registered accounting firm for Pharmos Corp.

Pharmos Corp. Designates Eric Fangmann as Acting President and Acting Chief Financial Officer

Pharmos Corp. announced that as previously disclosed, on November 15, 2012, Eric Fangmann was designated as the acting President and acting Chief Financial Officer. Mr. Fangmann, age 43, has been the Chief Financial Officer for Lloyd I. Miller, III for approximately two years. Prior to that time, Mr. Fangmann was an independent accounting and finance consultant who was principally engaged by either publicly traded or privately held entities to assist in independent analysis or agreed upon procedures.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PARS:US $0.08 USD 0.00

PARS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PARS.
View Industry Companies
 

Industry Analysis

PARS

Industry Average

Valuation PARS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMOS CORP, please visit www.pharmoscorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.